{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:58:45Z","timestamp":1773766725068,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cmi.2024.08.024","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T02:36:59Z","timestamp":1724812619000},"page":"1339-1340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection"],"prefix":"10.1016","volume":"30","author":[{"given":"Amy M.","family":"Beeson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall R.","family":"Reves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.08.024_bib1","series-title":"The end TB strategy","year":"2015"},{"key":"10.1016\/j.cmi.2024.08.024_bib2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.08.024_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1157\/13102264","article-title":"Pauta corta de isoniazida y rifampicina comparada con isoniazida para la infecci\u00f3n latente de tuberculosis. Ensayo cl\u00ednico aleatorizado","volume":"25","author":"Geijo","year":"2007","journal-title":"Enfermedades Infecc Microbiol Cl\u00edn"},{"key":"10.1016\/j.cmi.2024.08.024_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.08.024_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB","volume":"65","author":"Aspler","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2024.08.024_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cmi.2024.06.024","article-title":"One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial","volume":"30","author":"Huang","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.08.024_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.08.024_bib8","series-title":"WHO consolidated guidelines on tuberculosis","year":"2018"},{"key":"10.1016\/j.cmi.2024.08.024_bib9","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S1473-3099(21)00052-9","article-title":"Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis","volume":"21","author":"Rustage","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.024_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmi.2023.02.016","article-title":"Treatment of latent tuberculosis infection in incarcerated people: a systematic review","volume":"29","author":"Matucci","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.08.024_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study","volume":"74","author":"Doan","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.024_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5588\/pha.23.0026","article-title":"Shorter TB treatment regimens should be safer as well","volume":"13","author":"Rucsineanu","year":"2023","journal-title":"Public Health Action"},{"key":"10.1016\/j.cmi.2024.08.024_bib13","series-title":"Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations","author":"Seddon","year":"2015"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:39:43Z","timestamp":1762029583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1198743X24004245"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.07.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}